Clin2
NCT06912009Possibly a fitRecruiting

How long to treat blood clots in the lungs

Pulmonary Embolism

Part of Heart & circulation, Lungs & breathing clinical trials.

This trial looks at how long people need blood-thinning medicine after a serious blood clot in the lungs. It might help doctors find the best treatment length for each person.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older
  • You were in the intensive care unit at Hautepierre Hospital in France between 2014 and 2023
  • You had a blood clot in your lungs confirmed by a special scan
  • You received a strong blood thinner called unfractionated heparin
  • You did not have a low-risk clot (based on a score called sPESI)
  • You do not object to your medical data being used for research

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04355975Recruiting
Study follow-up outcomes after a lung blood clot

This trial looks at how people do after an acute pulmonary embolism (a blood clot in the lungs). It aims to understand real-world outcomes over follow-up and may help improve how care teams track patients after treatment.

Bern, Canton of Bern
NCT07603700Not yet recruiting
Treatment strategies for moderate-to-severe blood clots in the lungs

This real-world study compares different treatment approaches for pulmonary embolism (PE)—a serious blood clot in the lung arteries—in patients who are stable but at intermediate-to-high risk of complications. The goal is to understand which treatments work best and safest in everyday practice.

Nanjing, Jiangsu
NCT06453876Recruiting· Phase 3
Comparing clot removal, low-dose clot dissolver, and heparin for high-risk lung clot

This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.

Copenhagen
NCT07003646Recruiting
Treating acute pulmonary embolism with clot-dissolving or catheter procedures

This study looks at how well different treatments work for a blood clot in the lung (pulmonary embolism). It includes people who are getting or have already gotten a clot-dissolving medicine or a catheter procedure to remove the clot.

Aarhus
NCT06143969Recruiting
Ultrasound-guided clot-dissolving treatment for intermediate-high risk pulmonary embolism

This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.

Milan, Italia
NCT06348459Recruiting
Catheter treatment for severe pulmonary embolism

This study looks at how well a catheter (a thin tube) works to treat a serious type of blood clot in the lungs. It is for people who have a large clot that is causing problems like fast heart rate or low blood pressure.

Madrid, Madrid

Hear when a new Pulmonary Embolism trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.